Japan’s National Energy Development Organization To Start Large-Scale Alzheimer’s Disease Trial
This article was originally published in PharmAsia News
Executive Summary
To detect early signs of Alzheimer's disease in Japanese people and contribute to new drug development, Japan's National Energy Development Organization announced April 19 a plan to start a large scale trial in 36 facilities nationwide. The center plans to recruit 600 early stage patients and conduct various diagnostics in a 2-3 year period. Ten major Japanese drug companies including Astellas and seven device makers including GE Yokokawa Medical System also agreed to collaborate. NEDO plans to utilize magnetic resonance imaging and positron emission tomography technologies to measure brain size and memory loss. It will be the first such trial in Japan. (Click here for more - Japanese language